Wilks Brothers’s Pfizer PFE Stock Holding History

Wilks Brothers’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-38,366	Closed	-$1.6M	–	35
2018 Q3	$1.6M	Hold	38,366	–	–	0.19%	44
2018 Q2	$1.32M	Buy	+38,366	New	+$1.31M	0.14%	59

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wilks Brothers's PFE Position: Q4 2018 in Review

Wilks Brothers sold out of Pfizer (PFE) in Q4 2018, closing a stake of 38,366 shares — an estimated $1.6M sold.

Wilks Brothers first reported a position in PFE in Q2 2018 and held it in 2 quarters. The position peaked at $1.6M in Q3 2018. 2,403 funds tracked by Wall St. Rank hold PFE as of Q4 2018.

Wilks Brothers reported no remaining Pfizer position as of Q4 2018 after selling out during the quarter.
Wilks Brothers sold 38,366 Pfizer shares in Q4 2018, an estimated $1.6M.
Wilks Brothers first reported a position in Pfizer in Q2 2018 and held it in 2 quarters.
Wilks Brothers's Pfizer position peaked at $1.6M in Q3 2018.
2,403 funds tracked by Wall St. Rank held Pfizer as of Q4 2018.

Based on Wilks Brothers's 13F filing for Q4 2018, filed 13 Feb 2019.